EMERGENT BIOSOLUTIONS INC. Restructuring Charges
EMERGENT BIOSOLUTIONS INC. (EBS) reported Restructuring Charges of -$2.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. restructuring charges for the quarter ending 2025-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for the quarter ending 2025-09-30 was $300.00K, a 95.24% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for the quarter ending 2025-06-30 was -$1.10M, a 106.43% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for the quarter ending 2025-03-31 was -$1.30M.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for fiscal 2025 was -$2.10M, a 109.33% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for fiscal 2024 was $22.50M, a 23.21% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for fiscal 2023 was $29.30M.
- EMERGENT BIOSOLUTIONS INC. restructuring charges for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $300.00K derived: sum of 2 quarters · filed 2026-02-27 | -$800.00K derived: sum of 3 quarters · filed 2026-02-27 | -$2.10M 10-K · filed 2026-02-27 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-10-30 | -$800.00K derived: sum of 2 quarters · filed 2025-10-30 | -$2.10M 10-Q · filed 2025-10-30 | -$2.50M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | -$1.10M 10-Q · filed 2025-08-07 | -$2.40M 10-Q · filed 2025-08-07 | -$2.80M derived: sum of 3 quarters · filed 2026-02-27 | $3.50M derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | -$1.30M 10-Q · filed 2025-05-08 | -$1.70M derived: sum of 2 quarters · filed 2026-02-27 | $4.60M derived: sum of 3 quarters · filed 2026-02-27 | $21.70M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $5.90M derived: sum of 2 quarters · filed 2026-02-27 | $23.00M derived: sum of 3 quarters · filed 2026-02-27 | $22.50M 10-K · filed 2026-02-27 |
| 2024-09-30 | $6.30M 10-Q · filed 2025-10-30 | $23.40M derived: sum of 2 quarters · filed 2025-10-30 | $22.90M 10-Q · filed 2025-10-30 | $22.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $17.10M 10-Q · filed 2025-08-07 | $16.60M 10-Q · filed 2025-08-07 | $16.00M derived: sum of 3 quarters · filed 2026-02-27 | $36.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$500.00K 10-Q · filed 2025-05-08 | -$1.10M derived: sum of 2 quarters · filed 2026-02-27 | $19.20M derived: sum of 3 quarters · filed 2026-02-27 | $19.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $19.70M derived: sum of 2 quarters · filed 2026-02-27 | $19.60M derived: sum of 3 quarters · filed 2026-02-27 | $29.30M 10-K · filed 2026-02-27 |
| 2023-09-30 | $20.30M 10-Q · filed 2024-11-07 | $20.20M derived: sum of 2 quarters · filed 2024-11-07 | $29.90M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$100.00K 10-Q · filed 2024-08-07 | $9.60M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $9.70M 10-Q · filed 2024-05-02 | |||
| 2015-06-30 | $5.00M 10-Q · filed 2014-11-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2015-03-09 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $2.68M 10-K · filed 2015-03-09 | ||
| 2013-09-30 | $2.68M 10-Q · filed 2013-11-08 | |||
| 2013-03-31 | $1.84M 10-Q · filed 2013-05-03 | |||
| 2012-12-31 | $3.10M 10-K · filed 2013-03-08 | |||
| 2011-12-31 | $2.50M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |